Aimmune Therapeutics Inc. (NASDAQ:AIMT) has announced new data in its two-year study that shows the long-term efficacy of PALFORZIA daily treatment in peanut allergy patients. The company has also released findings from its third phase ARTEMIS trial that shows that peanut allergy patients aged 4 years to 17 years showed high satisfaction following daily PALFORZIA treatment.
PALFORZIA shows enhanced desensitization in peanut allergy patients
Patients that received daily treatment of PALFORZIA demon stared ongoing immunomodulation and enhanced desensitization rates. This increased over time compared to patients that received nondaily dosing. Over 80% of the patients treated with PALFORZIA were desensitized successfully to peanut proteins after two years of treatment. Similarly, the patients that were oi the daily dosing cohorts shower minimal adverse effect rates relative to those in nondaily dosing cohorts. Also, the general safety profile of extended PALFORZIA dosing was better compared to nondaily dosing.
The results from the two-year ARC004 study were a follow-on trial of the vita third phase PALISADE study. The company presented the results at the European Academy of Allergy and Clinical Immunology virtual congress.
FDA approved PALFORZIA In January
The FDA approved PALFORZIA in late January 2020 as the first peanut allergy therapy, and it is priced at $890 per month. It is meant to minimize peanut sensitivity by exposing the patient to a refined peanut flour version over time. The results indicated that patients were confident that the PALFORZIA treatment was convenient, effective, and easy to incorporate and administer in their daily lives. The company indicated that the effective way of treatment for patients is daily dosing for optimal results.
Daniel Adelman, the chief medical officer of Aimmune, indicated that they were delighted to provide insight on the safety profile and long-term efficacy of PALFORZIA. He added that results indicate that patients exhibited significant effects of modulation. He said that the ARTEMIS study was delighted with the majority of the participants completing the study. Further, Daniel indicated that patients pointed out that PALFORZIA was effective in managing peanut allergy.